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Aims: To study neuropsychological functioning of newly diagnosed children with acute lymphoblastic
leukaemia (ALL) within two weeks after diagnosis in order to determine the feasibility of a sibling controlled
prospective study design.
Methods: Fifty consecutive patients (median age at testing 6.6 years, range 4–12) were included in a
prospective, longitudinal, nationwide study. Treatment would include intrathecal and systemic
chemotherapy according to the DCLSG ALL-9 protocol. Children were evaluated with an extensive
neuropsychological battery including measures of intelligence, memory, attention, language, visual-
constructive function, and fine-motor abilities within two weeks after start of the chemotherapy. The control
group consisted of 29 healthy siblings (median age at testing 8.2 years, range 4–12), who were tested
,4 weeks after the patients’ assessment.
Results: Mean scores on Wechsler Intelligence Scales did not differ significantly between patients and
siblings; mean IQ scores for both the patients and the controls were high average. To examine specific
neuropsychological functions, norm scores based on the exact age were acquired by fitting procedures,
but no significant differences were found.
Conclusions: Neuropsychological assessment of patients during early hospitalisation is feasible. The results
indicate no adverse effect of illness and psychological factors on IQ and neuropsychological functioning of
patients with recently diagnosed ALL. The prospective design of this study of cognitive late effects of
chemotherapy will allow discrimination between adverse sequelae of disease and treatment.
A
cute lymphoblastic leukaemia (ALL) is the most
common form of childhood cancer. Approximately
80% of newly diagnosed children with ALL are curable
with modern treatment.1 2 Following this improved survival
rate, an increasing number of studies has focused on the
quality life of the survivors. Patients who have been treated
with cranial irradiation (CI) and additional chemotherapy
have shown intellectual deterioration and specific neuropsy-
chological deficits.3–5 To date, prospective longitudinal studies
on neuropsychological sequelae in children treated for ALL
with chemotherapy only are rare or have yielded inconsistent
results.6–8 These inconsistencies may be understood from less
suitable control groups, different ages at time of testing (age
effect), and selection of neuropsychological measures.
Moreover, pretreatment neuropsychological assessments
are rarely conducted. It is commonly thought that testing
shortly after diagnosis is not feasible because children
diagnosed with ALL are seriously ill and have to cope with
medical procedures and intensive treatment immediately
after diagnosis. Leukaemia or leukaemia treatment can
furthermore cause emotional, non-organic distress in
patients and families, which may influence test behaviour
of the children.
In 1999, we initiated a prospective longitudinal and
nationwide study in the Netherlands, which includes siblings
as controls, applies a comprehensive test battery, and has a
broad age spectrum. Here we report the results of the
neuropsychological assessment in patients shortly after
diagnosis, and their healthy siblings. The results will
eventually be used to investigate both early and late
neuropsychological effects of chemotherapy according to
the Dutch Childhood Leukaemia Study Group (DCLSG)
ALL-9 protocol. In this report, we review the results of
neuropsychological assessment shortly after diagnosis of both
patients and their healthy siblings.
METHODS
Patients and sibling controls
From January 1999 to June 2001, 79 consecutive patients
from six participating paediatric oncology centres in the
Netherlands were eligible for this study. Criteria of eligibility
were: newly diagnosed patients with high or standard risk
ALL; age between 4 years and 12 years 3 months; and Dutch
as primary language. Informed consent was obtained
according to each hospital’s rules. Patients with initial CNS
leukaemia and patients with pre-existent disorders that could
interfere with normal cognitive development were excluded.
Sixteen (20%) parents refused participation because of the
expected burden, and 19 (24%) cases were missed due to
logistical problems.
Between March 1998 and January 1999, six consecutive
patients has been enrolled in a pilot study in the hospital
which coordinated the study. These patients did not
significantly differ from the children in the main study;
hence, a combined group of 50 patients entered the study.
The control group consisted of 25 healthy siblings who met
the same inclusion criteria as the patients. If the patient had
more than one sibling, the child (1) closest in age to the
patient and (2) the same sex was chosen. Table 1 shows the
characteristics of patients and siblings.
Abbreviations: ALL, acute lymphoblastic leukaemia; CI, cranial
irradiation; DCLSG, Dutch Childhood Leukaemia Study Group; SES,
socioeconomic status
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Treatment
Patients had just started treatment according to the national
chemotherapy only DCLSG ALL-9 protocol, including vincris-
tine, dexamethasone, daunorubicin, and triple intrathecal
(IT) therapy as CNS prophylaxis. This protocol is similar to
the DCLSG ALL-6 protocol.9–11 The patients had received one
cycle of vincristine, dexamethasone, daunorubicin, and triple
IT therapy before their first assessment.
Study design
Patients were individually evaluated within two weeks after
diagnosis and start of treatment. Siblings were individually
assessed within four weeks after the patients’ evaluation.
Patients and siblings did not significantly differ with respect
to age at testing and gender. There were no indications that
patients with or without siblings differed in socioeconomic
status (SES). To maximise standardisation, all participants
were nationwide tested by one qualified child neuropsychol-
ogist who travelled to the hospitals were the children were
treated.
Patients and healthy sibling controls were evaluated with
an age appropriate comprehensive standardised neuropsy-
chological test battery (table 2). Children aged 4–6 years were
administered a developmental screening test and measures of
intelligence, visual-motor integration, and, if >5 years, fine-
motor functioning. Participants aged 6–12 years were
assessed with a more extensive test battery. The neuropsy-
chological assessment of these children took about three
hours, including measures of intelligence and specific
cognitive functions as verbal-auditory and visual memory,
visual-motor integration, attention, cognitive flexibility,
verbal fluency, and fine-motor functioning. If necessary,
the assessment was split into two sessions.
Statistical analysis
Performances of patients were compared to those of sibling
controls using non-directional two tailed Student’s t tests for
paired groups.
For the Wechsler Pre-School and Primary Scales of
Intelligence (WPPSI-R), Experimental Dutch-Flemish ver-
sion, and for the Wechsler Intelligence Scale for Children-
revised (WISC-R, Dutch version), mean norm scores are 100
(SD=15). For the remaining tests, norms have been
acquired by fitting procedures based on the raw scores and
the exact ages resulting in norm scores (mean=50;
SD=10). The fitting procedures were based on the published
norm data (means and standard deviations for different age
groups) in the respective test manuals or other publications.
This procedure enables comparisons of standardised scores
between subjects of any specific age.21 22 Significance levels
were established at p , 0.05. Statistical analyses were
performed using version 10 of the Statistical Package for
the Social Sciences (SPSS Inc., Chicago, IL, USA).
RESULTS
Included patients (n=50) did not significantly differ from
missing patients (n=35) in terms of sex, age at diagnosis,
and initial characteristics of disease and prognostic risk
group. We had no indication of differences in socioeconomic
status between included and missing patients. The latter
mainly emanated from two hospitals; patients were missed
due to illness of the psychologists who should have referred
eligible patients. Patients and siblings aged 4–6 years at
diagnosis were assessed as essentially normal on the Denver
Developmental Scales. Patients aged 4–6 years scored
significantly higher than siblings on WPPSI-R FS-IQ and
WPPSI-R VIQ (table 3). Comparing patients aged 6–13
and siblings, no significant differences were found for any
WISC-R factor. IQs were high average for patients on the
WPPSI-R and both patients and siblings on the WISC-R.
Table 4 shows results for the remaining cognitive
measures. No significant differences between the groups
were found for any test. Overall, patients and siblings had
average scores.
Table 1 Characteristics of patients and siblings at the
first neuropsychological evaluation shortly after diagnosis
of ALL
Group
Male Female Age at testing
n (%) n (%) Median (range)
Patients 30 (60) 20 (40) 6.6 (4–12)
Healthy controls
(siblings)
11 (38) 18 (62) 8.2 (4–12)
Table 2 Neuropsychological battery
Neuropsychological domain Measures Age No. patients No. siblings
Mental, motor, and social
development
Denver Developmental Scales13 4–6 17 6
Intelligence Wechsler Pre-School and Primary Scales of Intelligence (WPPSI-R), 10 subtests14 4–6
FS-IQ 12 6
V-IQ 13 6
P-IQ 12 6
Intelligence Wechsler Intelligence Scale for Children (WISC-R), 10 subtests15 6–13
FS-IQ 26 23
V-IQ 30 23
P-IQ 26 23
Concentration factor 28 23
Perceptual organisation 25 23
Verbal-auditory learning and
memory
Dutch version of Rey’s Auditory-Verbal Learning Test (RAVLT)16 6–13 26 23
Visual memory Rey-Osterreith Complex Figure Test delayed (CFT) recall17 6–13
Verbal fluency Animal naming fluency test17 6–13 30 23
Sustained attention/speed Bourdon-Vos; self-paced, continuous performance cancellation task12 6–13 20 21
Cognitive flexibility Wisconsin Card Sorting Test (WCST)18 6–13 26 23
Perceptual-motor skills Beery Developmental Test of Visual-Motor Integration (VMI)19 4–13 47 28
Visuospatial constructional
ability/planning
Rey-Osterreith Complex Figure Test (CFT) copy16 6–13 26 23
Fine-motor function Purdue Pegboard20 5–13 29 27
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DISCUSSION
We have shown that recently diagnosed children with the life
threatening disease ALL can be reliably assessed with an
extensive standardised neuropsychological test battery
shortly after diagnosis. An important observation in this
study was that the majority, even the very young children,
enjoyed the assessment, which was rather a distraction
among numerous medical procedures than an emotional
burden. Moreover, this study is strengthened by the inclusion
of healthy siblings as controls, who were also pleased to be
involved in the study and enjoyed the special attention. This
control group enables appropriate comparison with the
healthy population. Decrements in test results within the
patient group can be detected, even if the results are still
above average. For accurately assessing changes, precise
standardised age scores are essential. Therefore the validity of
this study is enhanced by using a fitting procedure for the
construction of test norms which provides standardised
scores based on the exact age of the subjects.21 22
Our data correspond with the few other studies offering
baseline pretreatment in newly diagnosed patients which
also showed no obvious different results.7
The present study can be criticised for the high number of
missing patients, which could possibly account for bias in
these test results. However, this is unlikely because included
patients did not significantly differ from missed patients
concerning demographic and initial disease characteristics.
Missed patients should mainly have been referred by two ill
psychologists. Fortunately, patients in these hospitals repre-
sent a random patient population, hence we have no
indication that characteristics of the missed children differed
from those who could be included. With the current numbers
we would detect IQ differences of 0.7 SD (10.5 IQ points) to
obtain an adequate power of 80%. To illustrate the meaning
of 10.5 SD, a difference between 105 and 95 would be
significant, but both IQs are considered average and children
with both IQs would be in a regular school class. We could
not control for SES. Given the overall average results, bias
does not seem likely. In general, patients showed greater
standard deviation on both the intelligence tests and
neuropsychological tests. However, differences between
patients and siblings did not result from one or few
individuals with extreme scores.
The norm scores of the Experimental Dutch-Flemish
version of the WPPSI-R were recently evaluated as dispu-
table, which could explain the above-average IQs in the
young patients (table 3). However, if the patients’ IQs are
overrated, we could expect above average IQs in the siblings
as well. There were no demographic differences explaining
the IQ differences between patients and siblings aged 4–6
years. The scores of the children tested with the WISC-R are
high average as a result of the Flynn effect, accounting for an
Table 3 Results of intelligence testing; comparison of patients to siblings at the first evaluation shortly after diagnosis of ALL
Wechsler scales
Patients Siblings
t value p value 95% CIMean (SD) Mean (SD)
4–6 years
WPPSI-R FS-IQ 114.7 (16.7) 101.5 (7.3) 2.32 0.034 1.2 to 25.2
WPPSI-R V-IQ 116.1 (14.5) 99.5 (8.4) 2.59 0.019 3.1 to 30.1
WPPSI-R P-IQ 108.8 (13.9) 106.0 (19.6) 0.36 0.726 214.0 to 19.7
6–12 years
WISC-R FS-IQ 108.1 (15.4) 107.1 (10.9) 0.26 0.799 26.8 to 8.8
WISC-R V-IQ 106.9 (14.1) 107.0 (10.8) 20.04 0.970 27.3 to 7.0
WISC-R P-IQ 109.0 (17.5) 108.0 (13.3) 0.22 0.825 28.0 to 10.0
WISC-R perceptual organisation 109.5 (15.9) 106.0 (14.1) 0.80 0.428 25.3 to 12.2
WISC-R concentration 106.5 (15.0) 108.0 (12.1) 20.38 0.707 29.2 to 6.3
WPPSI-R; V-IQ (information, similarities, arithmetic, vocabulary, digit span), P-IQ (object assembly, block design, mazes, picture completion, animal pegboard).
WISC-R; V-IQ (information, similarities, arithmetic, vocabulary, digit span), P-IQ (picture completion, block design, object assembly, coding, mazes), Perceptual
organisation factor (picture completion, block design, object assembly, mazes), Concentration factor (arithmetic, digit span, coding).
Table 4 Results of neuropsychological tests comparing the ALL group with siblings at the first evaluation shortly after diagnosis
Test measures
Patients Siblings
t value p value 95% CIMean (SD) Mean (SD)
RAVLT
Immediate recall 50.6 (8.0) 52.2 (8.7) 20.67 0.506 26.4 to 3.2
Delayed recall 52.4 (11.0) 49.2 (9.8) 1.06 0.295 22.9 to 9.2
Fluency Test: animal naming 63.7 (10.5) 60.4 (9.7) 1.17 0.248 22.4 to 9.0
Bourdon-Vos
Speed 53.8 (14.3) 48.8 (8.7) 1.36 0.183 22.5 to 12.4
Accuracy 51.0 (10.4) 49.7 (7.1) 0.45 0.658 24.4 to 6.8
WCST
Errors 49.4 (11.1) 50.7 (8.8) 20.44 0.664 27.1 to 4.6
Perseverations 49.3 (10.7) 50.8 (8.6) 20.54 0.591 27.1 to 4.1
Trials administered 50.0 (10.7) 50.7 (8.9) 20.28 0.784 26.5 to 4.9
Beery VMI 47.6 (9.7) 51.4 (11.6) 21.52 0.133 28.7 to 1.2
Rey-Osterreith CFT
Copy 54.3 (5.9) 54.7 (5.5) 20.26 0.795 23.7 to 2.9
Delayed recall 44.5 (8.4) 46.6 (6.1) 20.91 0.370 26.5 to 2.5
Purdue Pegboard
Dominant hand 45.5 (10.5) 45.7 (10.1) 20.11 0.916 25.8 to 5.2
Non-dominant hand 48.3 (8.3) 46.4 (8.6) 0.81 0.424 22.8 to 6.4
Both hands 49.0 (11.1) 48.3 (7.3) 0.25 0.804 24.5 to 5.7
Assembly 52.5 (11.7) 51.9 (9.1) 0.20 0.840 25.1 to 6.3
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IQ rise of about 6 points, since test norms were collected in
the early 1980s.23 If evaluated with more recent test norms
these children would probably have average results.
Generally, it is often suggested that emotional, non-organic
distress influences the test results. However, such an effect is
very unlikely given the normal outcome. Even measures of
attention and memory, known to be sensitive for emotional
distress,24 did not differ between patients and siblings.
Conclusion
The present data strongly suggest that patients do not suffer
from neuropsychological deficits related to acute disease or
early treatment. In the future, patients’ baseline scores can be
used to discriminate between possible adverse sequelae of
disease and/or treatment and eventually, to optimise treat-
ment protocols compromising between high cure rate and
good quality of life. Ideally, neuropsychological assessment
early after hospitalisation also selects patients who need early
intervention for mental or academic deficits, but this was not
the aim of this study.
Neuropsychological assessment of children with ALL
shortly after diagnosis with sibling controls is feasible and
essential to discriminate between adverse sequelae of
treatment. Prospective, longitudinal study designs should
become the standard for evaluating possible treatment
effects.
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